While DAAs have revolutionized the treatment of viral infections, they are not without challenges: - Cost: DAAs can be expensive, limiting access in low-resource settings. - Resistance: Viral mutations can lead to resistance against DAAs, necessitating combination therapies and ongoing drug development. - Access: Regulatory and logistical barriers can delay the availability of DAAs in certain regions.
